Editorial
| Preface | PDF HTML |
| Run Wang | 1-3 |
Original Article
| Penile rehabilitation after radical prostatectomy: patients’ attitude and feasibility in China | PDF HTML |
| Yi-Jun Shen, Jian Li, Ding-Wei Ye | 4-9 |
| Surgical treatment of Peyronie’s disease by modified 16-dot placation in China | PDF HTML |
| Wen Ji Li, Haijun Yao, Ke Zhang, Zhikang Cai, Jun Da, Mingxi Xu, Zhong Wang | 10-14 |
Review Article
| Peyronie’s disease: current therapy | PDF HTML |
| Clay M. Pendleton, Run Wang | 15-23 |
| Current rehabilitation strategy: clinical evidence for erection recovery after radical prostatectomy | PDF HTML |
| Arthur L. Burnett | 24-31 |
| Anterior urethral stricture review | PDF HTML |
| Marshall J. Stein, Rowena A. DeSouza | 32-38 |
| Peyronie’s disease: contemporary review of non-surgical treatment | PDF HTML |
| Laurence A. Levine | 39-44 |
| Premature ejaculation: do we have effective therapy? | PDF HTML |
| Ege Can Serefoglu, Theodore R. Saitz, Landon Trost, Wayne J.G. Hellstrom | 45-53 |
| A critical look at descriptive epidemiology of sexual dysfunction in Asia compared to the rest of the world - a call for evidence-based data | PDF HTML |
| Ronald W. Lewis | 54-60 |
| The science of vacuum erectile device in penile rehabilitation after radical prostatectomy | PDF HTML |
| Haocheng Lin, Run Wang | 61-66 |
| Strategies for maintaining penile size following penile implant | PDF HTML |
| King Chien Joe Lee, Gerald B. Brock | 67-73 |
| Sexual function and male cancer | PDF HTML |
| Luca Incrocci | 74-81 |
Perspective
Review Article
Expert Opinions on Challenging Cases
Brief Report
Commentary
Below are the latest Translational Andrology and Urology articles published online ahead of print publication.
Editorial
- Refining treatment for the men who need it: lessons from the PIVOT trial
-
-
Michael R. Abern, Matvey Tsivian, Thomas J. Polascik
- Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?
-
-
Ilse Van Brussel, Amaryllis H. Van Craenenbroeck, Dorien M. Schrijvers, Nathalie Cools
- Immunotherapy in renal cell cancer: the more the merrier?
-
-
Jorge Camarero, Sol Ruiz
- Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
-
-
Matthias M. Heck, Jürgen E. Gschwend, Margitta Retz
Research Highlight
- Enzalutamide: the emperor of all anti-androgens
-
-
Emmanuel S. Antonarakis
- Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
-
-
Amy M Pick, Zara Risoldi Cochrane
Opinion
- Regenerative technology for future therapy of erectile dysfunction
-
-
Ji-Kan Ryu, Jun-Kyu Suh
- TGF-β mediated DNA methylation in prostate cancer
- Mast cells, estrogens, and cryptorchidism: A histological based review
- Systemic implications of urinary stone disease
- Denosumab: Delay of bone metastasis in men with nonmetastatic
- Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need
- Milestones for development of tivozanib for kidney cancer therapy
- Erectile dysfunction: Doctors perspectives on patients concerns
- Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy
- Role of hormonal therapy for prostate cancer: Perspective from Japanese experiences
- Regenerative technology for future therapy of erectile dysfunction
- Phytotherapy: emerging therapeutic option in urologic disease
- The complexity of sunitinib dosing in renal cell cancer patients
- Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer
- Micro-RNAs, next-generation molecular markers in male infertility field




